Photys Therapeutics entered a multi-year collaboration and license agreement with Novo Nordisk to develop proximity-based therapeutics for a cardiometabolic disease target leveraging Photys’ PHosphorylation Inducing Chimeric Small molecules technology. https://hubs.li/Q0309GTD0
Contract Pharma’s Post
More Relevant Posts
-
Ensure your #mRNA vaccine & therapeutic products analytical development success! 🚀 We hope to see you at the mRNA-Based Therapeutics Summit in Boston (July 29-31). Find out how Intertek experts can support your mRNA therapeutics development from early-stage characterization to late-stage development and commercialization! Please stop by our booth or contact us to schedule a meeting: Diogo Rodrigues and Mairita Ntoulovi. 🌍 Event: 4th Annual mRNA-Based Therapeutics Summit 📅 When: July 29-31, 2024 📍 Where: Boston, MA #mRNATherapeutics #mRNATherapeuticsSummit #mRNABasedTherapeuticsSummit
-
-
Back-to-back development candidates progressing into the clinic is no mean feat! Following on the footsteps of VYN201 which progressed into Phase 2b last month; this week we are delighted to share that dosing of the first participants in the Phase 1a trial of VYN202 has taken place. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immuno-inflammatory diseases. VYN202 was discovered by the team at Tay Therapeutics before being licensed to VYNE Therapeutics who are leading clinical development. Top-line data is expected in the second half of 2024. https://lnkd.in/ePG4eb7V https://lnkd.in/eGtRw7Ty
-
Session spotlight 🌟 At the mRNA-Based Therapeutics Summit Europe, Maren von Fritschen, PhD, Shirley Hopper, Constanze Blume, Julia Djonova and Ulrike Jaegle will lead the panel discussion on “A European Industry & Regulatory Perspective on the Development & Approval of mRNA Medicines”. To dive deeper into this exciting session and more, view the event program: https://lnkd.in/e6zrkvWC #rna #mrnaeurope #mrna #messengerrna
-
-
FDA's CDER recently issued a draft guidance: Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics. In this new Advancing RNA article, Peter Calcott of calcott consulting provides a summary and analysis. The public comment period ends January 14, 2025. https://lnkd.in/dD7VrGuU #oligonucleotides #drugdevelopment
-
-
Your weekly CRISPR Medicine News is here! 🔇 What happened in industry this week? News from Intellia Therapeutics, Inc., Allogene Therapeutics, and Fate Therapeutics Inc. 🔇New clinical trials on the way - Korro Bio, Inc. and Tune Therapeutics 🔇Research advances 🔇Reviews, and more! Get it all right here 👇 https://lnkd.in/dDaKA_ps #crisprmedicinenews #crisprmedicine #crisprnews #geneediting #cmnweekly
-
-
⏰With only 2 weeks to go, we now have limited passes remaining. Register now to sit beside the 100+ RNA targeting experts. Hear the latest insights from leading biopharma like Base4, Remix Therapeutics, Rgenta Therapeutics Inc., Biogen, Accent Therapeutics, Inc. and more. As the definitive and most comprehensive event for RNA-targeting experts, this is your opportunity to bring effective small molecule drugs to patients faster by advancing the understanding of the relationship between RNA structure and function, deciphering conformational dynamics, and designing small molecules that can effectively bind and stabilize RNA structures. Find Out More: https://ter.li/u5ozoe8 Secure Your Spot: https://ter.li/u5ozue8 #RNADrugDiscovery #RNAResearch #RNAInnovation #RNACollaboration
-
-
The complement system's amplification loop offers promising targets for emerging complement therapeutics, providing hope for improved disease outcomes. Our latest case study explores the potential of Properdin Functional Assessment in evaluating the modulation of the amplification loop and the alternative pathway. Download your free copy now! #ComplementingLifeScience #AnswesinLifeScience #Complementsystem #Complementbiology #AlternativePathway #Properdin #ComplementTherapeutics #DrugDevelopment https://hubs.ly/Q02BGTqT0
Functional Assessment of Properdin or AP-modulation?
svarlifescience.com
-
New in circRNA research! CircRNA-based therapeutics Current opinions and clinical potential. In this review, researchers provide a comprehensive overview of current knowledge on circRNA biogenesis and functions, and summarize recent advances in various technologies for circRNA research. Read more: https://lnkd.in/etwjRcV9 #circRNA #clinicalresearch #mRNA #paper #biotechresearch
CircRNA-based therapeutics: Current opinions and clinical potential
the-innovation.org
-
You won't want to miss the upcoming webinar on the HEAL #Pain Therapeutics Development Program (#PTDP). Monday July 29, 2024 3:00 PM ET. This webinar will inform and provide participants with an opportunity to ask questions about PTDP and the #NIH funding announcement, RFA-NS-24-019 whose purpose is to support #preclinical optimization and development of safe, effective, and #nonaddictive small molecule and biologic therapeutics to treat pain. The goal of PTDP is to accelerate promising early therapeutic molecules and facilitate their readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) or other Phase II clinical studies. Link to register for the webinar: https://lnkd.in/g4ftETip
